This article is more than 5 years old. Information may no longer be current.
Xen gel stent maintains reduced IOP at 1 year
Click Here to Manage Email Alerts
BARCELONA — Reduced IOP and reduced need for medications was maintained at 1 year after implantation of the Xen gel stent, according to a speaker here.
“We like to call the AqueSys Xen gel stent a hybrid system,” Ingeborg Stalmans, MD, PhD, said at the European Society of Cataract and Refractive Surgeons meeting. The ab interno glaucoma device is less invasive than trabeculectomy, but also targets the subconjunctival space as trabeculectomy does.
Ingeborg Stalmans
“AqueSys attempted to combine the best of both worlds and design a stent that gives you a less invasive surgery and maintains the efficacy,” she said.
Stalmans shared results from a prospective, nonrandomized, multicenter study, which included 63 patients with primary open angle glaucoma, pigmentary glaucoma or pseudoexfoliative glaucoma who were implanted with the gel stent.
Mean IOP preoperatively was 22.1 mm Hg. Mean IOP postoperatively at 1 year was 12.9 mm Hg. Mean number of medications needed preoperatively was 3.2, and mean number of medications needed at 1 year postoperatively was 1.1.
“I think this data confirms that [this] new device has an excellent safety profile with an IOP in the low teens at 1 year, which is rather exceptional,” Stalmans said. — by Nhu Te
Disclosure: Stalmans reports she is a consultant for AqueSys and Allergan.